COST

997.49

-0.33%↓

PG

157.17

-1.24%↓

MO

64.41

-1.5%↓

CL

94.14

-0.28%↓

SYY

86.47

-0.03%↓

COST

997.49

-0.33%↓

PG

157.17

-1.24%↓

MO

64.41

-1.5%↓

CL

94.14

-0.28%↓

SYY

86.47

-0.03%↓

COST

997.49

-0.33%↓

PG

157.17

-1.24%↓

MO

64.41

-1.5%↓

CL

94.14

-0.28%↓

SYY

86.47

-0.03%↓

COST

997.49

-0.33%↓

PG

157.17

-1.24%↓

MO

64.41

-1.5%↓

CL

94.14

-0.28%↓

SYY

86.47

-0.03%↓

COST

997.49

-0.33%↓

PG

157.17

-1.24%↓

MO

64.41

-1.5%↓

CL

94.14

-0.28%↓

SYY

86.47

-0.03%↓

Search

Lifecore Biomedical Inc

Closed

SectorConsumer defensive

7.38 -2.12

Overview

Share price change

24h

Current

Min

7.11

Max

7.46

Key metrics

By Trading Economics

Income

-7.9M

-10M

Sales

-5.3M

31M

Profit margin

-32.116

Employees

406

Dividends

By Dow Jones

Next Earnings

13 lut 2026

Market Stats

By TradingEconomics

Market Cap

31M

272M

Previous open

9.5

Previous close

7.38

News Sentiment

By Acuity

50%

50%

57 / 133 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lut 2026, 17:25 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 lut 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 lut 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9 lut 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 lut 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 lut 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 lut 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 lut 2026, 22:01 UTC

Earnings

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 lut 2026, 21:59 UTC

Earnings

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 lut 2026, 21:59 UTC

Earnings

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 lut 2026, 21:58 UTC

Earnings

Friedman Industries 3Q Sales $168M >FRD

9 lut 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

9 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lut 2026, 21:48 UTC

Earnings

Friedman Industries 3Q EPS 43c >FRD

9 lut 2026, 21:17 UTC

Earnings

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 lut 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 lut 2026, 21:04 UTC

Earnings

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 lut 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 lut 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 lut 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9 lut 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 lut 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9 lut 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9 lut 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 lut 2026, 17:41 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 lut 2026, 17:31 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 lut 2026, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

9 lut 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lut 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 lut 2026, 17:16 UTC

Earnings

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Peer Comparison

Price change

Lifecore Biomedical Inc Forecast

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Sentiment

By Acuity

57 / 133 Ranking in Consumer defensive

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat